Day: March 18, 2023

HII Celebrates 200 Graduates of The Newport News Shipbuilding Apprentice School Graduate Rosa Rainey rings the bell during commencement exercises for HII’s Newport News Shipbuilding Apprentice School held Saturday, March 18, 2023. (Photo by Lexi Whitehead/HII)NEWPORT NEWS, Va., March 18, 2023 (GLOBE NEWSWIRE) — HII (NYSE: HII) hosted commencement exercises today, celebrating 200 graduates of the company’s Apprentice School at Newport News Shipbuilding (NNS). The ceremony was held at Liberty Live Church in Hampton. Virginia Gov. Glenn Youngkin delivered the keynote commencement address. “Newport News Shipbuilding graduates: You build America, you run America, you are the backbone of America, and we are so proud of you,” Youngkin said. “As Governor of Virginia, it’s never been clearer that the road to American exceptionalism...

Banco Comercial Português, S.A. informs about upgrade of deposits rating to Investment Grade and Long-Term Issuer Default Rating to ‘BB+’ by Fitch RatingsAttachment2023 03 17 Upgrade Fitch EN

Dupixent®(dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitisMore than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one weekParis and Tarrytown, N.Y. March 18, 2023. Positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented today. The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent...

More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week TARRYTOWN, N.Y. and PARIS, March 18, 2023 (GLOBE NEWSWIRE) —  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis. The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD)...

New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15% Rapid and significant improvements were achieved including individuals reaching a 75% reduction of Eczema Area and Severity Index (EASI-75) as early as Week 1 and in Investigator Global Assessment (IGA) Success as early as Week 2 In both studies, roflumilast cream improved atopic dermatitis across multiple efficacy endpoints while demonstrating favorable safety and tolerability Incidences of adverse events were low, with no adverse event occurring in more than 3.5% of subjects in either armWESTLAKE VILLAGE, Calif., March 18, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations...